Advertisement

Bristol-Myers Squibb Co. and AstraZeneca said Wednesday the Food and Drug Administration is reviewing their application for fixed dose of Onglyza in combination with metformin as a treatment for diabetes.

Onglyza, made by Bristol-Myers and AstraZeneca, is already approved as a diabetes treatment and metformin is a widely-used generic diabetes pill.

The company did not provide an estimate for an FDA decision.

Advertisement
Advertisement